desipramine has been researched along with A-V Dissociation in 5 studies
Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.
desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Desipramine was given to 34 outpatients aged 20 to 51 years who had primary major depressive disorder but who were otherwise in good health." | 5.07 | 2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults. ( Cooper, TB; Johnson, MH; Nelson, LD; Ribner, HS; Stern, SL; Suckow, RF, 1991) |
| "In a 6-week study of children and adolescents with attention deficit disorder with hyperactivity (ADDH) in which desipramine (DMI) was highly effective and well tolerated, the mean maximal daily oral dose in the DMI-treated patients (N = 31) was 4." | 5.06 | A double-blind placebo controlled study of desipramine in the treatment ADD: II. Serum drug levels and cardiovascular findings. ( Baldessarini, RJ; Biederman, J; Goldblatt, A; Harmatz, JS; Knee, D; Wright, V, 1989) |
| "Desipramine treatment instituted at a daily dosage of 75 mg for depressive equivalents of head, chest, and abdominal pain was increased to 1,000 mg daily over a 12-year interval with minimal side effects." | 1.26 | Withdrawal from long-term high-dose desipramine therapy. Clinical and biological changes. ( Brown, GM; Gupta, RN; Harman, J; Moldofsky, H; Murphy, JT; Stancer, HC, 1978) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, GM | 1 |
| Stancer, HC | 1 |
| Moldofsky, H | 1 |
| Harman, J | 1 |
| Murphy, JT | 1 |
| Gupta, RN | 1 |
| Bartels, MG | 1 |
| Varley, CK | 1 |
| Mitchell, J | 1 |
| Stamm, SJ | 1 |
| Stern, SL | 1 |
| Ribner, HS | 1 |
| Cooper, TB | 1 |
| Nelson, LD | 1 |
| Johnson, MH | 1 |
| Suckow, RF | 1 |
| Biederman, J | 1 |
| Baldessarini, RJ | 1 |
| Wright, V | 1 |
| Knee, D | 1 |
| Harmatz, JS | 1 |
| Goldblatt, A | 1 |
3 trials available for desipramine and A-V Dissociation
| Article | Year |
|---|---|
Pediatric cardiovascular effects of imipramine and desipramine.
Topics: Adolescent; Anxiety Disorders; Child; Depressive Disorder; Desipramine; Double-Blind Method; Electro | 1991 |
2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults.
Topics: Adult; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Depressive Disorder; Desipramine; Ele | 1991 |
A double-blind placebo controlled study of desipramine in the treatment ADD: II. Serum drug levels and cardiovascular findings.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Cardiovascular System; Child; Desipramine | 1989 |
2 other studies available for desipramine and A-V Dissociation
| Article | Year |
|---|---|
Withdrawal from long-term high-dose desipramine therapy. Clinical and biological changes.
Topics: Adult; Desipramine; Electrocardiography; Electroencephalography; Growth Hormone; Heart Block; Humans | 1978 |
Safety of desipramine.
Topics: Adolescent; Cardiovascular System; Child; Desipramine; Heart Block; Humans; Male | 1989 |